The estimated Net Worth of Jeffrey M. Dayno is at least $1.31 Миллион dollars as of 3 November 2022. Dr Dayno owns over 15,000 units of Harmony Biosciences stock worth over $559,200 and over the last 8 years he sold HRMY stock worth over $13,534. In addition, he makes $734,245 as Chief Medical Officer at Harmony Biosciences.
Sign up
Dr D HRMY stock SEC Form 4 insiders trading
Dr has made over 12 trades of the Harmony Biosciences stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of HRMY stock worth $123,300 on 3 November 2022.
The largest trade he's ever made was exercising 18,200 units of Harmony Biosciences stock on 19 October 2021 worth over $149,604. On average, Dr trades about 5,134 units every 145 days since 2016. As of 3 November 2022 he still owns at least 15,000 units of Harmony Biosciences stock.
You can see the complete history of Dr Dayno stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Jeffrey M. Dayno M.D. biography
Dr. Jeffrey M. Dayno M.D. is the Chief Medical Officer at Harmony Biosciences.
What is the salary of Dr D?
As the Chief Medical Officer of Harmony Biosciences, the total compensation of Dr D at Harmony Biosciences is $734,245. There are 1 executives at Harmony Biosciences getting paid more, with John Charles Jacobs M.B.A. having the highest compensation of $933,938.
How old is Dr D?
Dr D is 64, he's been the Chief Medical Officer of Harmony Biosciences since . There are no older and 5 younger executives at Harmony Biosciences.
Insiders trading at Harmony Biosciences
Over the last 4 years, insiders at Harmony Biosciences have traded over $224,163,932 worth of Harmony Biosciences stock and bought 514,681 units worth $12,537,009 . The most active insiders traders include Holdings A/S Novo, Andreas Wicki и Antonio J. Gracias. On average, Harmony Biosciences executives and independent directors trade stock every 19 days with the average trade being worth of $2,907,691. The most recent stock trade was executed by Sandip Kapadia on 29 March 2024, trading 15,000 units of HRMY stock currently worth $559,200.
What does Harmony Biosciences do?
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
What does Harmony Biosciences's logo look like?
Complete history of Dr Dayno stock trades at Harmony Biosciences
Harmony Biosciences executives and stock owners
Harmony Biosciences executives and other stock owners filed with the SEC include:
-
John Charles Jacobs M.B.A.,
Pres, CEO & Director -
Dr. Jeffrey M. Dayno M.D.,
Chief Medical Officer -
Jeffrey Dierks M.B.A.,
Exec. VP & Chief Commercial Officer -
Andrew Serafin J.D., M.B.A.,
Exec. VP & Chief Strategy Officer -
Jeffrey S. Aronin,
Founder & Non-Exec. Chairman -
Patricia L. Bank,
Investor Relations Officer -
Nancy Leone,
Head of Corp. Communications -
Tricia Glover,
Chief Compliance Officer -
Christian Ulrich,
Gen. Counsel -
Sharon Goldbach,
Head of Facilities Operations & Exec. Admin. -
David Bradshaw,
Head of Technical Operations -
Sandip S. Kapadia CPA, M.B.A.,
Chief Financial Officer -
Holdings A/S Novo,
10% owner -
Iv Pharma Holdings, Llc Val...,
-
Fund Trust Ii Marshman,
10% owner -
Andrew Serafin,
CHIEF STRATEGY OFFICER -
Linda M Szyper,
-
Antonio J. Gracias,
-
R. Mark Graf,
-
Eric L Motley,
Director -
Jeffrey S Aronin,
Director -
Jeffrey Dierks,
CHIEF COMMERCIAL OFFICER -
John C Jacobs,
PRESIDENT, CEO -
Jack Nielsen,
-
Sandip Kapadia,
CHIEF FINANCIAL OFFICER -
Jeffrey M. Dayno,
PRESIDENT, CEO -
Gary Sender,
-
Juan A. Sabater,
-
Peter Anastasiou,
-
Kumar Budur,
CHIEF MEDICAL OFFICER